HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke

HCID 763Erstellt: 4. November 2026

Guanidinoessigsure

GUANIDINOACETIC ACID · GLYCOCYAMINE · GUANIDOACETIC ACID · NSC 1901 · NSC 26360 · NSC 227847 · BetacyaMine · GLYCOYAMINE

https://huagongshe.com/de/chemical/763

Identifikatoren & physikalische Daten

CAS No.	352-97-6
Summenformel	C3H7N3O2
Durchschnittliche Molmasse	117,11 g/mol
SMILES	NC(N)=NCC(=O)O
InChIKey	BPMFZUMJYQTVII-UHFFFAOYSA-N
PubChem CID	763
ChEMBL	CHEMBL281593
ChEBI	CHEBI:16344
EC No.	206-529-5
DTXSID	DTXSID50861885
Lokaler Name	Guanidinoessigsure

Chemische & physikalische Eigenschaften

XLogP	-1,6
Polarare Oberfläche (TPSA)	102
H-Brücken-Donoren	3
H-Brücken-Akzeptoren	3
Frei drehbare Bindungen	2
Schwere Atome	8
Formalladung	0
Komplexität	116
Arzneimittel	Pharmaceuticals -> Listed in ZINC15
Löslichkeit	3.6 mg/mL at 15 °C6 M NaOH : 50 mg/mL, clear, colorless3.6g/L(15 ºC)
Physical Description	Solid
Collision Cross Section	134.6 Å² [M+Na]+ [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]124.8 Å² [M+H]+ [CCS Type: DTMethod: single field calibrated with Agilent tune mix (Agilent)]126.88 Å² [M+H]+ [CCS Type: DTMethod: stepped-field]134.4 Å² [M+Na]+
Schmelzpunkt	300 °C(lit.)
Siedepunkt	218.88°C (rough estimate)
Dichte	1.4020 (rough estimate)
Brechungsindex	1.4900 (estimate)
Lagerbedingungen	Keep in dark place,Inert atmosphere,Room temperature
pKa (Säurekonstante)	2.82(at 25℃)
Aggregatzustand	Solid
Farbe	White to Off-White
Merck	14,4495
BRN	1759179
InChI	1S/C3H7N3O2/c4-3(5)6-1-2(7)8/h1H2,(H,7,8)(H4,4,5,6)
InChIKey	BPMFZUMJYQTVII-UHFFFAOYSA-N
SMILES	NC(=N)NCC(O)=O
CAS Datenbank	352-97-6(CAS DataBase Reference)
EPA chemische Informationen	Glycocyamine (352-97-6)

Sicherheit & Vorschriften

GHS-Einstufung	This chemical does not meet GHS hazard criteria for 2.2% (1 of 46) of reports.WarningH315 (97.8%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 46 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Regulatorische Informationen	Regulation (EC) No 1831/2003 (amended)
Hazard Classes and Categories	Skin Irrit. 2 (97.8%)
Treatment	Chronic Exposure: Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored. Acute Exposure: EYES: irrigate opened eyes for several minutes under running water. INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice.
Gesundheitliche Auswirkungen	Acute exposure to guanidoacetic acid can lead to some mild skin and eye irritation. Chronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease. Chronically high levels of guanidoacetic acid are associated with at least 4 inborn errors of metabolism including: Argininemia, Guanidinoacetate methyltransferase deficiency, Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency) and S-Adenosylhomocysteine (SAH) Hydrolase Deficiency.
Expositionspfade	Endogenous, Ingestion, Dermal (contact)
Toxizitätsübersicht	Uremic toxins such as guanidinoacetic acid are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869)

CAS No.

352-97-6

Summenformel

C3H7N3O2

Durchschnittliche Molmasse

117,11 g/mol

SMILES

NC(N)=NCC(=O)O

InChIKey

BPMFZUMJYQTVII-UHFFFAOYSA-N

PubChem CID

763

ChEMBL

CHEMBL281593

ChEBI

CHEBI:16344

EC No.

206-529-5

DTXSID

DTXSID50861885

Lokaler Name

Guanidinoessigsure

Chemische & physikalische Eigenschaften

XLogP

-1,6

Polarare Oberfläche (TPSA)

102

H-Brücken-Donoren

H-Brücken-Akzeptoren

Frei drehbare Bindungen

Schwere Atome

Formalladung

Komplexität

116

Arzneimittel

Pharmaceuticals -> Listed in ZINC15

Löslichkeit

3.6 mg/mL at 15 °C6 M NaOH : 50 mg/mL, clear, colorless3.6g/L(15 ºC)

Physical Description

Solid

Collision Cross Section

134.6 Å² [M+Na]+ [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]124.8 Å² [M+H]+ [CCS Type: DTMethod: single field calibrated with Agilent tune mix (Agilent)]126.88 Å² [M+H]+ [CCS Type: DTMethod: stepped-field]134.4 Å² [M+Na]+

Schmelzpunkt

300 °C(lit.)

Siedepunkt

218.88°C (rough estimate)

Dichte

1.4020 (rough estimate)

Brechungsindex

1.4900 (estimate)

Lagerbedingungen

Keep in dark place,Inert atmosphere,Room temperature

pKa (Säurekonstante)

2.82(at 25℃)

Aggregatzustand

Solid

Farbe

White to Off-White

Merck

14,4495

BRN

1759179

InChI

1S/C3H7N3O2/c4-3(5)6-1-2(7)8/h1H2,(H,7,8)(H4,4,5,6)

InChIKey

BPMFZUMJYQTVII-UHFFFAOYSA-N

SMILES

NC(=N)NCC(O)=O

CAS Datenbank

352-97-6(CAS DataBase Reference)

EPA chemische Informationen

Glycocyamine (352-97-6)

Sicherheit & Vorschriften

GHS-Einstufung

This chemical does not meet GHS hazard criteria for 2.2% (1 of 46) of reports.WarningH315 (97.8%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 46 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Regulatorische Informationen

Regulation (EC) No 1831/2003 (amended)

Hazard Classes and Categories

Skin Irrit. 2 (97.8%)

Treatment

Chronic Exposure: Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored. Acute Exposure: EYES: irrigate opened eyes for several minutes under running water. INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice.

Gesundheitliche Auswirkungen

Acute exposure to guanidoacetic acid can lead to some mild skin and eye irritation. Chronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease. Chronically high levels of guanidoacetic acid are associated with at least 4 inborn errors of metabolism including: Argininemia, Guanidinoacetate methyltransferase deficiency, Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency) and S-Adenosylhomocysteine (SAH) Hydrolase Deficiency.

Expositionspfade

Endogenous, Ingestion, Dermal (contact)

Toxizitätsübersicht

Uremic toxins such as guanidinoacetic acid are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869)